menu
    • menu
    [{"orgOrder":0,"company":"Fuji Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"||Estrogen receptor||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fuji Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Fuji Pharma \/ Fuji Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Fuji Pharma \/ Fuji Pharma"},{"orgOrder":0,"company":"Fuji Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"||Estrogen receptor||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fuji Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Fuji Pharma \/ Fuji Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Fuji Pharma \/ Fuji Pharma"},{"orgOrder":0,"company":"Fuji Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ICELAND","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fuji Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fuji Pharma \/ Fuji Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fuji Pharma \/ Fuji Pharma"},{"orgOrder":0,"company":"Fuji Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Vedolizumab","moa":"||Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Preclinical","graph3":"Fuji Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Pharma \/ Fuji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Fuji Pharma \/ Fuji Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Fuji Pharma

    Menu

    Fuji Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $45.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mithra to Receive EUR 2.5 Million Milestone Payment from Fuji Pharma under ESTELLE® Licensing Agreement

                            Details : Under the agreements, Fuji Pharma obtains the rights to commercialize and advance the develoopment of Estelle, Mithra’s oral contraceptive product candidate based on Estetrol, for the treatment of Japanese patients with dysmenorrhea or endometriosis, i...

                            Product Name : Estelle

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 23, 2023

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $45.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $45.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma Under Estelle® Licensing Agreement

                            Details : Under the agreements, Fuji Pharma obtains the rights to commercialize and advance the develoopment of Estelle, Mithra’s oral contraceptive product candidate based on Estetrol, for the treatment of Japanese patients with dysmenorrhea or endometriosis, i...

                            Product Name : Estelle

                            Product Type : Other Small Molecule

                            Upfront Cash : $29.0 million

                            March 08, 2023

                            Lead Product(s) : Estetrol,Drospirenone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $45.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vedolizumab,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan

                            Details : The new agreement adds another biosimilar candidate to the partnership between Alvotech and Fuji, first announced in 2018, bringing the total number of proposed biosimilar products that the companies are partnering on to six.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 23, 2022

                            Lead Product(s) : Vedolizumab,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Fuji Pharma

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and Fuji Pharma Extend Biosimilar Partnership in Japan

                            Details : The companies have announced extension on their exclusive strategic partnership for the commercialization of four biosimilar medicines in Japan. The initial pipeline contains biosimilar candidates aimed at treating various therapeutic conditions for pati...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 16, 2020

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth